Skip to main content
Premium Trial:

Request an Annual Quote

Gene Logic's Q3 Revenues Increase 22 Percent as Losses Narrow 70 Percent

NEW YORK (GenomeWeb News) — Gene Logic today said third-quarter revenues rose 22 percent as R&D spending increased 4 percent and net loss narrowed by 70 percent.
Total receipts for the three months ended Sept. 30 rose to $4.5 million from $3.7 million year over year and came largely from the company’s genomic-services business, which posted flat revenues compared to the same quarter in 2006. Receipts from the company’s drug-repositioning business swelled to $841,000 from $6,000 in the year-ago period.
R&D spending increased to $2.7 million from $2.6 million year over year.
Gene Logic said net loss decreased to $7.9 million from $26.7 million in the year-ago period.  
As of Sept. 30, Gene Logic, which last week said it will sell its genomic assets to Ocimum Biosolutions for $10 million, had $22.6 million in cash and equivalents and $8.9 million in marketable securities.

The Scan

Dropped Charges

The US Justice Department has dropped visa fraud charges against five Chinese researchers, according to the Wall Street Journal.

More Kids

The Associated Press says Moderna is expanding its SARS-CoV-2 vaccine study to included additional children and may include even younger children.

PNAS Papers on Rat Clues to Human Migration, Thyroid Cancer, PolyG-DS

In PNAS this week: ancient rat genome analysis gives hints to human migrations, WDR77 gene mutations in thyroid cancer, and more.

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.